The Efficacy and Safety of Monoclonal Antibodies That Target Alpha-Synuclein in Parkinson's Disease: A Systematic Review.

Parkinsons Dis · 2026 · PMC13392413 · PMID 42495570

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

nominally significantno p-value reported

Nominally significant differences were reported in MDS‐UPDRS Part 3 for the low‐dose cohort and in Montreal Cognitive Assessment scores for the high‐dose cohort, but both used 80% confidence intervals without adjustment for multiplicity, limiting reliability.

also in 7,732 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.